SG10201906981TA - Methods and reagents for the assessment of gestational diabetes - Google Patents

Methods and reagents for the assessment of gestational diabetes

Info

Publication number
SG10201906981TA
SG10201906981TA SG10201906981TA SG10201906981TA SG10201906981TA SG 10201906981T A SG10201906981T A SG 10201906981TA SG 10201906981T A SG10201906981T A SG 10201906981TA SG 10201906981T A SG10201906981T A SG 10201906981TA SG 10201906981T A SG10201906981T A SG 10201906981TA
Authority
SG
Singapore
Prior art keywords
assessment
gestational diabetes
reagents
methods
kits
Prior art date
Application number
SG10201906981TA
Other languages
English (en)
Inventor
Michael Chorev
Jose Halperin
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG10201906981TA publication Critical patent/SG10201906981TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201906981TA 2013-12-03 2014-12-03 Methods and reagents for the assessment of gestational diabetes SG10201906981TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911306P 2013-12-03 2013-12-03
US201461946373P 2014-02-28 2014-02-28
US201461945860P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
SG10201906981TA true SG10201906981TA (en) 2019-09-27

Family

ID=53274086

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201906981TA SG10201906981TA (en) 2013-12-03 2014-12-03 Methods and reagents for the assessment of gestational diabetes

Country Status (11)

Country Link
US (1) US10732186B2 (https=)
EP (2) EP3077815B1 (https=)
JP (2) JP6542219B2 (https=)
KR (1) KR20160092006A (https=)
CN (2) CN109917125A (https=)
AU (1) AU2014360539A1 (https=)
CA (1) CA2932607A1 (https=)
IL (2) IL245925B (https=)
MX (1) MX371298B (https=)
SG (1) SG10201906981TA (https=)
WO (1) WO2015084994A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109538A2 (en) * 2011-02-10 2012-08-16 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
CN105181869B (zh) * 2015-09-21 2016-05-18 南京医科大学 一种巨大儿辅助诊断标志物的应用
WO2017123666A2 (en) * 2016-01-11 2017-07-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. In vivo positron emission tomography-based perfusion/blood pool imaging using labeled erythrocytes
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
RU2703342C1 (ru) * 2018-11-19 2019-10-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации Прогнозирование развития гестационного сахарного диабета у первородящих юного возраста
RU2710498C1 (ru) * 2019-03-04 2019-12-26 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ прогнозирования высокого риска развития пролиферативной диабетической ретинопатии у беременных с сахарным диабетом 1 типа
CN112924682B (zh) * 2019-12-05 2023-02-10 张曼 尿液纤维蛋白原α链蛋白及其多肽片段在正常妊娠中的应用
KR102525374B1 (ko) 2020-12-16 2023-04-24 가톨릭대학교 산학협력단 고위험 임신성 당뇨병 예측모델 설계 방법 및 장치
CN113009152B (zh) * 2021-02-19 2022-05-10 山东省大健康精准医疗产业技术研究院 一种糖基化cd59酶联免疫检测试剂盒及其制备方法与应用
CN112904009B (zh) * 2021-02-19 2022-03-18 山东莱博生物科技有限公司 一种检测糖基化cd59的磁性微球检测试剂盒及其应用
WO2022241236A2 (en) * 2021-05-13 2022-11-17 Mellitus, Llc Methods and reagents for protein analysis
EP4207210A1 (en) * 2021-12-29 2023-07-05 Diabeloop Computerized method to assess confidence in a main predictive output determined by a predictive model

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2619568B1 (fr) 1987-08-21 1989-07-07 Centre Nat Rech Scient Polymeres derives du polystyrene, leurs procedes de preparation et leurs applications pour l'analyse et la purification de molecules d'origine biologique
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9110962D0 (en) * 1991-05-21 1991-07-10 Ici Plc Process
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU670108B2 (en) * 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US5407912A (en) 1993-04-19 1995-04-18 Akzo, N.V. Method of treating bladder cancer with a keyhole limpet hemocyanin composition with enhanced anti-tumor activity
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5670377A (en) * 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6323361B1 (en) * 1997-04-17 2001-11-27 Corning Inc. Photocurable halofluorinated acrylates
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP1075286A2 (en) * 1998-05-06 2001-02-14 Isotechnika, Inc. 13c glucose breath test for the diagnosis of diabetes
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
JP2003055366A (ja) * 2001-08-20 2003-02-26 Shiseido Co Ltd ラクトン誘導体、並びに、これを有効成分とする植物成長調整剤および発根誘導剤
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US20040067496A1 (en) 2002-10-07 2004-04-08 Robert Pytela System for production and screening of monoclonal antibodies
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
CA2612303C (en) 2004-06-17 2018-03-13 Jose Halperin Anti-glycated cd59 antibodies and uses thereof
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7833725B2 (en) * 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20120027658A1 (en) * 2010-07-30 2012-02-02 Karwacki Christopher J Oxidation Catalysts Useful for Ambient Temperature Operation
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
WO2012109538A2 (en) * 2011-02-10 2012-08-16 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
CN102590491B (zh) * 2012-02-06 2014-12-10 中国人民解放军第三军医大学第一附属医院 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells

Also Published As

Publication number Publication date
EP3077815B1 (en) 2019-07-17
KR20160092006A (ko) 2016-08-03
IL245925B (en) 2019-02-28
WO2015084994A1 (en) 2015-06-11
JP2017502267A (ja) 2017-01-19
CN105934671A (zh) 2016-09-07
IL264559A (en) 2019-02-28
JP6542219B2 (ja) 2019-07-10
US20160299150A1 (en) 2016-10-13
CN109917125A (zh) 2019-06-21
US20170108505A2 (en) 2017-04-20
EP3620793A1 (en) 2020-03-11
CA2932607A1 (en) 2015-06-11
IL245925A0 (en) 2016-07-31
MX2016007123A (es) 2017-02-15
AU2014360539A1 (en) 2016-06-23
MX371298B (es) 2020-01-23
US10732186B2 (en) 2020-08-04
EP3077815A4 (en) 2017-06-21
CN105934671B (zh) 2019-04-19
JP2019191186A (ja) 2019-10-31
EP3077815A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
SG10201906981TA (en) Methods and reagents for the assessment of gestational diabetes
HK1223361A1 (zh) 用於预测肠易激综合征诊断的途径特异性测定
WO2013096822A3 (en) Test device for optical and electrochemical assays
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
MY161291A (en) Antibody, kit and method for determination of amyloid peptides
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
EP3991848A3 (en) High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2015158868A3 (en) Methods, kits and apparatus for expanding a population of cells
WO2015148609A3 (en) Immunoassays using colloidal crystals
WO2014091490A3 (en) Diagnosis of autoimmune diseases using a specific antibody profile
WO2015084888A8 (en) Task selections associated with text unputs
WO2012175602A3 (en) Elisa for calprotectin
WO2012139052A3 (en) Antibody biomarkers for diabetes
WO2018085431A8 (en) Filamin a binding proteins and uses thereof
WO2014160237A3 (en) Methods of prognosing preeclampsia
MX2021003484A (es) Metodos para detectar efecto(s) hook asociado(s) con analito(s) de interes durante o que resulta(n) de la realizacion de ensayo(s) de diagnostico.
GB201119585D0 (en) Assay
WO2015091902A3 (en) Determination of platelet-mirnas in alzheimer's disease
WO2017209553A3 (ko) 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2018176030A3 (en) Antibodies and immunoassays for detection of bmp-15 and gdf-9 isoforms
WO2018226098A3 (en) METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF
MX2021004684A (es) Anticuerpos especificos para apoj glucosilada y usos de los mismos.
WO2015105806A3 (en) Antibodies against glioma biomarkers
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer